Peplomycin

O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@@](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)([H])C(NCCC2=NC(C3=NC(C(NCCCN[C@H](C4=CC=CC=C4)C)=O)=CS3)=CS2)=O)=O)=O)([H])[C@H](C5=CNC=N5)O[C@H]6[C@H]([C@H]([C@H](O)[C@H](CO)O6)O)O[C@]7([H])[C@H]([C@H]([C@H](O)[C@@H](CO)O7)OC(N)=O)O

[1]Carter SK, et al. Peplomycin. Cancer Treat Rev. 1984 Dec;11 (4) :303-5. |[2]Asano Y, et al. A case of peplomycin-induced scleroderma. Br J Dermatol. 2004 Jun;150 (6) :1213-4. |[3]Okamura H, et al. Peplomycin-induced apoptosis in oral squamous carcinoma cells depends on bleomycin sensitivity. Oral Oncol. 2001 Jun;37 (4) :379-85. |[4]Osaki T, et al. Peplomycin, a bleomycin derivative, induces myofibroblasts in pulmonary fibrosis. Int J Exp Pathol. 2001 Aug;82 (4) :231-41.